In this paper, the efficacy and clinical safety of antiuric acid formula in the treatment of hyperuricemia and gout were studied. Uric acid enzyme inhibitor (potassium oxazine acid) was used to model, and analgesic, anti-inflammatory and safety experiments were carried out. The result shows that antiuric acid formula could significantly reduce the levels of uric acid and urea nitrogen in serum of model rats. To some extent, it can reduce the pathological changes of liver and kidney caused by hyperuricemia, reduce the number of writhing in mice induced by chemical stimulation of pain, increase the pain threshold of mice stimulated by hot plate, and obviously reduce the swelling degree of ears induced by xylene in mice. The maximum dosage test determined its edible safety. Therefore, antiuric acid formula can obviously reduce the content of uric acid in the body, has anti-inflammatory and analgesic effect, acute toxicity indicates that it is nontoxic.